Consensus BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Real-time Estimate Cboe BZX Other stock markets 10:46:32 2024-04-23 am EDT			5-day change	1st Jan Change
91.66 ^USD	+2.42%		+0.66%	-5.13%

Apr. 22	BioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS Says	MT
Apr. 15	Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	MT

Evolution of the average Target Price on BioMarin Pharmaceutical Inc.

Price target over the last 5 years

History of analyst recommendation changes

8b507cf2e9f720bb9a60d7a871b8.O9yFnFn2KkOQoPDjdeq2IKjPTpmR9kqVty3Kngc8Lhs.dprSqzHAf3v0_5esI4fdeez3AOvHsgjdwlyIym1FFk98re31LYRgCdPsnw~711878e8d4232146083781e3222af704

Analyst Recommendations on BioMarin Pharmaceutical Inc.

Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15	MT
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01	MT
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside	Feb. 23	MT
BofA Securities Cuts BioMarin Pharmaceutical Price Target to $150 From $170, Maintains Buy Rating	Jan. 26	MT
If you didn’t have enough signs, here’s more	Nov. 15
ANALYST RECOMMENDATIONS : Datadog, Fair Isaac, HSBC, Home Depot, Wise...	Nov. 15
BMO Capital Adjusts Price Target on BioMarin Pharmaceutical to $100 From $102, Keeps Outperform Rating	Nov. 03	MT
UBS Trims BioMarin Pharmaceutical Price Target to $119 From $120, Maintains Buy Rating	Nov. 02	MT
Barclays Cuts BioMarin Pharmaceutical's Price Target to $111 From $125, Overweight Rating Maintained	Nov. 02	MT
Cantor Fitzgerald Adjusts Price Target on BioMarin Pharmaceutical to $100 From $120, Maintains Overweight Rating	Nov. 02	MT
ANALYST RECOMMENDATIONS : Airbnb, Intel, CVS, Caterpillar, Qualcomm...	Nov. 02
Morgan Stanley Cuts Price Target on BioMarin Pharmaceutical to $117 From $125, Keeps Overweight Rating	Nov. 02	MT
Bernstein Upgrades BioMarin to Market Perform From Underperform, Price Target is $82	23-10-23	MT
ANALYST RECOMMENDATIONS : Amazon, Procter & Gamble, Salesforce, Unilever, Walgreens Boots...	23-10-23
ANALYST RECOMMENDATIONS : Amex, Biogen, Dollar General, Fortinet, Whitbread...	23-10-13
UBS Initiates Coverage on BioMarin Pharmaceutical With Buy Rating, $120 Price Target	23-09-18	MT
Wedbush Lifts BioMarin Pharmaceutical's PT to $78 From $71, Continues to See VOXZOGO/ACH as Main Driver of Growth; Keeps Neutral Rating	23-09-14	MT
Wedbush Adjusts BioMarin Pharmaceutical Price Target to $71 From $70, Maintains Neutral Rating	23-08-31	MT
Morgan Stanley Adjusts Price Target on BioMarin Pharmaceutical to $125 From $129, Maintains Overweight Rating	23-08-01	MT
Stifel Adjusts Price Target on BioMarin Pharmaceutical to $108 From $118, Maintains Buy Rating	23-08-01	MT
Wedbush Lowers BioMarin Pharmaceutical's PT to $70 From $73, Notes Uncertainty Around VOXZOGO's Growth Trajectory, ROCTAVIAN Headwinds; Keeps Neutral Rating	23-08-01	MT
Scotiabank Starts BioMarin Pharmaceutical at Sector Perform With $95 Price Target	23-07-27	MT
BofA Securities Cuts BioMarin Pharmaceutical's Price Target to $185 From $200, Maintains Buy Rating	23-07-21	MT
BMO Capital Upgrades BioMarin Pharmaceutical to Outperform From Market Perform, Price Target is $102	23-07-05	MT
ANALYST RECOMMENDATIONS : Anglo American, Gladstone, GSK, Netflix...	23-07-05

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

89.49 USD

Average target price

110.4 USD

Spread / Average Target

+23.39%

High Price Target

140 USD

Spread / Highest target

+56.44%

Low Price Target

80 USD

Spread / Lowest Target

-10.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioMarin Pharmaceutical Inc.

Wedbush
BofA Securities
BMO Capital
UBS
Barclays
Cantor Fitzgerald
Morgan Stanley
Bernstein
Stifel Nicolaus
Scotiabank
Canaccord Genuity
Citigroup
Piper Sandler
Guggenheim
Credit Suisse
Baird
Oppenheimer
SVB Securities LLC
Jefferies & Co.
JPMorgan Chase
RBC Capital Markets
Goldman Sachs
SVB Leerink
William Blair & Co.
Evercore ISI

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar